• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Broad Institute receives $100 million gift

Broad Institute receives $100 million gift

November 15, 2013
CenterWatch Staff

American philanthropists and entrepreneurs Eli and Edythe Broad are investing an additional $100 million into the Broad Instituteto launch a new decade of transformative work to harness recent biomedical discoveries to benefit patients.

This gift brings their total contributions to the institute to $700 million since its founding nearly a decade ago and makes the Broads the second largest donors ever to a university, hospital or research institute for biomedical research.

“When we made our first investment to create the Broad Institute, we shared Eric Lander’s vision that discoveries in biomedical research held the key to beating devastating disease and improving people’s lives,” said Eli Broad, founder of The Broad Foundations. “As the Broad Institute nears its tenth anniversary, it has already made transformative discoveries, building on the successes of the Human Genome Project. Our latest investment is intended to catalyze the next decade of innovation and discovery. Our goal is to enable the Broad Institute community to continue to take bold risks, bring together the brightest minds in the field and pursue game-changing breakthroughs that are needed to make a difference in science and medicine.”

The Broad Institute was founded in 2003, bringing together scientists from across the MIT and Harvard communities, including the Harvard-affiliated teaching hospitals, and from diverse disciplines including biology, medicine, chemistry and computer science.

Through collaborations that span the Broad Institute’s partner institutions and other organizations across the globe, the Broad has pioneered scientific advances aimed at developing a deeper, more precise understanding of disease biology and opening up entirely new paradigms for diagnosis and treatment. These approaches include discovering the genes and molecular underpinnings of major human diseases ranging from diabetes to cancer to infectious disease;

applying this knowledge to systematically map the “wiring diagram” of cell control, revealing the key vulnerabilities that underlie disease; and discovering and developing diverse chemical compounds that can target those vulnerabilities.

Broad researchers have developed and applied state-of-the-art genomic methods, which have propelled the discovery of hundreds of genes at play in major human diseases, including type 2 diabetes and early-onset heart disease; psychiatric diseases such as autism and schizophrenia; autoimmune diseases such as inflammatory bowel disease and rheumatoid arthritis; infectious diseases such as malaria and tuberculosis; and dozens of cancers.

The Broads’ $100 million gift is their fourth gift to the Broad Institute. In 2004, an initial $100 million investment launched the institute, and was followed a year later by a second $100 million. In 2008, the Broads pledged $400 million to endow and establish the Broad Institute as an independent nonprofit scientific research institution, making it a permanent part of the biomedical landscape.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing